ME Therapeutics advances two CD19/CD22 in vivo CAR lead constructs in preclinical testing

• ME Therapeutics advanced two lead in vivo CD19/CD22 CAR mRNA constructs, aiming to reduce tumor escape from CD19 loss.
• Head-to-head preclinical testing is underway to compare expression and functional performance ahead of final candidate selection.
• Final construct selection is targeted for Q4 2026, followed by formulation into T cell-targeting lipid nanoparticles for in vivo delivery.
• Progressed a liver-detargeted STING mRNA sequence, showing reduced STING protein expression in human hepatocytes in vitro.
• Next step for the STING program is lipid nanoparticle formulation for in vivo testing, targeting greater tumor specificity and safety.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ME Therapeutics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080900BIZWIRE_USPR_____20260908_BW596473) on September 08, 2026, and is solely responsible for the information contained therein.